Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — Proceedings from the 2026 Annual ONS Cong...

Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — Proceedings from the 2026 Annual ONS Cong...

Featuring perspectives from Dr Farrukh T Awan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, moderated by Dr Kahl, including the following topics: • Introduction: Biology of Non-Hodgkin Lymphoma (NHL) (00:00) • Current Role of CD20 x CD3 Bispecific Antibodies in NHL (4:49) • Role of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma (DLBCL) (27:48) • Optimal Application of Loncastuximab Tesirine for Patients with DLBCL and Follicular Lymphoma (41:43) • Role of Bruton Tyrosine Kinase (BTK) Inhibitors Alone or with Anti-CD20 Antibodies for Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) (1:00:43) • Combining BTK Inhibitors with Bcl-2 Inhibitors (1:31:15) • Current and Future Role of Noncovalent BTK Inhibitors in CLL (1:41:30) CME information and select publications (https://researchtopractice.com/ONS202...)